Skip to content

Laetitia Benard



Benard Laetitia
Laetitia Benard



Laëtitia leads the Paris Intellectual Property practice and is co-head of Allen & Overy's Life Sciences Group worldwide. Laëtitia is a litigator specializing in domestic and cross-border patent litigation.

She has a wealth of expertise in all intellectual property areas, more particularly having acted in numerous complex patent disputes involving pharmaceutical and high tech companies. She also advises on patent portfolios, patent validity, and freedom to operate issues. She has specific knowledge of the life sciences field, in which she also advises on various regulatory and contractual matters such as price regulation, advertisement for medicines, transfers of technology and anti-bribery rules.

Laëtitia frequently publishes on life sciences regulatory topics and has written a number of clients alerts on issues such as biosimilars, the-EFPIA-Transparency-Initiative, and the online sale of medicines. Her publications include "Interim injunctions over patents – The French practice" in Managing Intellectual Property (February 2013); "Overview of Life Sciences law in France" in Chambers Life Sciences Guide 2013; "Why France is a good forum for preliminary injunctions in patent matters" in Global Business Magazine, 2012; "Supplementary Protection Certificates – CJEU provides welcome clarifications" International Who's Who Legal - Life Sciences, 2012; "Preliminary injunctions in Europe: an overview in the field of patents", The Handbook of European IP Management, 2012.

Laëtitia is a recognized practitioner by « Best Lawyers » since 2013 in Biotechnology and Life Sciences Practice and Intellectual Property Law.



Global leader in Patents 


"Litigator Laëtitia Bénard heads both the IP practice in Paris and Allen & Overy’s life sciences group globally, gathering plaudits from the market for her finely tuned high-tech and pharmaceutical advice." IAM Patent 1000 - France 2019

Laëtitia Bénard - Ranked Gold in Litigation (IAM Patent 1000 - France 2019)

Global Leader in Life Sciences - Patent Litigation 2019, Patents 2019 and National Leader France - Life Sciences, France - Patents 

Silver for enforcement and litigation; prosecution and strategy 
WTR 1000- 2018-2019

Leading Individual 


"Best in Patent" Euromoney LMG Europe Women in Business Law Awards 2019

"Intellectual Property Lawyer of the Year" Benchmark Litigation Europe 2019 

"Laëtitia Bénard specialises in pharmaceutical patent litigation and is lauded as "an excellent lawyer for contentious matters." Another source enthuses: "She is famous for being a hard-working, excellent lawyer for patent matters," adding: "She is a determined and effective presence in court."" CHAMBERS & PARTNERS 2019 - France (Pharma/Life Science)

"Laëtitia Bénard is a market leader in IP and primarily acts on patent litigation cases for pharmaceutical companies. She is highly respected by clients and peers who highlight her client dedication and industry knowledge. She assisted Pfizer with a patent litigation case concerning the validity of a second medical use patent." CHAMBERS & PARTNERS 2019 - France (Intellectual Property)

"Leading Life sciences practitioner in France." - Euromoney Expert Guides: Best of the Best Global Awards 2019 

"Litigation Star for IP Litigation in France " Benchmark Europe 2019

IP Star” and “Top 250 Woman in IP” Managing IP – Patents and Trademark 2018

“Laëtitia Bénard is described by clients as "very impressive" and "very knowledgeable about the pharmaceutical industry as a whole." She is further praised for her cross-border capabilities and her "pragmatic and result-oriented" nature.” – Chambers & Partners Europe 2018 - Pharma/Life Sciences– France

“Laëtitia Bénard is head of the firm's Paris IP practice. Clients say: "She is able to grasp complex issues and thinks about the big picture.” – Chambers & Partners Europe 2018 - Intellectual Property – France

"Peers shower Bénard with praise: ‘She’s an extremely hard worker with a tremendous reputation. Her importance in the IP scene is unquestionable.’.” - IAM PATENT 1000 – FRANCE, 2018

Pharmaceuticals powerhouse Bénard’s extremely impressive in court and has a strong understanding of procedural issues.” WTR 1000 – 2018

""Laëtitia is managing the team well," says a market commentator. According to one client, Bénard is "highly skilled in litigation". Another client adds: "Laëtitia is the go-to lawyer for life sciences companies and her skills are second to none." MANAGING IP EUROPE, 2018

"Laëtitia Bénard heads the IP and litigation department: 'She is incredibly capable, knows her cases extremely well, anticipates questions before they arise and has a complete grasp of all aspects of IP litigation issues in France'.” IAM Patent 1000 – France, 2017

"Practice head Laëtitia Bénard is ‘very impressive and the must-use lawyer in the life sciences area’." Legal 500 – EMEA 2017 – Intellectual Property: Patents - France

"Laëtitia Bénard excels in all aspects of IP with a particular focus on the life sciences sector."  Chambers & Partners Europe 2017 - Intellectual Property – France

"Laëtitia Bénard is described as a 'very present and important' practitioner in the market. She has particular expertise in the life sciences sector." Who's Who Legal - France 2017

News & insights

Key regulatory topics

Publications: 17 FEBRUARY 2020

Key Regulatory Topics: Weekly Update 07 February - 13 February 2020

Allen & Overy publish weekly updates on key regulatory topics affecting the financial services sector.

Read more

News: 12 FEBRUARY 2020

Allen & Overy advises Oesterreichische Kontrollbank on its $1.5bn bond offering

Allen & Overy advised Oesterreichische Kontrollbank on legal aspects of its public offering of $1.5 billion of 1.500% Guaranteed Global Notes due 2025. The bonds are guaranteed by the Republic of Austria and will be listed on the regulated market of the Luxembourg Stock Exchange.

Read more

News: 11 FEBRUARY 2020

Allen & Overy hosts Inaugural Canadian Banks Workshop

Allen & Overy hosted our Inaugural Canadian Banks Workshop in Toronto, Ontario on January 30, which brought together legal and business teams from RBC, Scotiabank, BMO and T.D. Bank, for a one-day seminar on how to handle a shifting regulatory and legal landscape.

Read more
Isra vision

News: 10 FEBRUARY 2020

Allen & Overy advises ISRA VISION AG on takeover offer

Allen & Overy is advising Darmstadt-based ISRA VISION AG (ISRA) in connection with the takeover offer that was announced by Swedish company Atlas Copco AB before the start on Monday.  The takeover offer is part of an industrial partnership agreed between ISRA and Atlas Copco and values ISRA at EUR 1.1 billion.

Read more



Allen & Overy LLP
52 avenue Hoche
75008 Paris

View office →



Admitted to the Bar, Paris, 2000


Post Graduate Degree, Industrial Property, University of Paris II Panthéon Assas, 1999

Post Graduate Degree, French Civil Law, University of Paris I Panthéon Sorbonne, 1998

Pro-bono experience

  • Advising French non-profit organisation "Autistes Sans Frontières" ("Autistics Without Borders")


Published work

  • ‘Brexit’: time is of the essence for life sciences innovators – LSIPR (Life Sciences Intellectual Property Review) – June 2016
  • La juridiction unifiée du brevet (JUB) : un atout indéniable pour l'Europe, La Lettre des juristes d'affaires, July 2014
  • La juridiction unifiée du brevet (JUB) reçoit un soutien croissant des entreprises, Option Droit et Finance, July 2014 co-authored with David Por
  • France’s Biosimilar law may set trend inside the EU, Law 360, February 2014, co-authored with Eveline Van Keymeulen
  • L’Acte II de l’exception culturelle sur la scène du numérique, Les Echos, June 2013
  • "France" chapter, International Copyright Law book, Global Law & Business, May 2013, co-authored with Alexandre Rudoni and Olivia Klimis
  • Overview of Life Sciences law in France, Chambers Life Sciences Guide 2013, co-authored with Olivier Fréget, David Por and Olivia Klimis
  • Interim injunctions over patents, The French practice, Managing Intellectual Property, co-authored with Olivia Klimis
  • Choisir la stratégie juridique adéquate pour valoriser sa marque - Décryptage avec Laëtitia Bénard, Les Echos, December 2012
  • Comparative Advertising for generics in Germany and France after L’Oréal v Bellure, PTMG Law Lore & Practice, December 2012, co-authored with Oscar Benito, Rainer Kaase and Ralf Möller
  • Il faut sauver le projet de brevet unitaire européen, Option Droit & Affaires, September 2012, co-authored with Olivia Klimis
  • Preliminary injunctions in Europe: an overview in the field of patents, The Handbook of European IP Management, May 2012
  • Trade secrets protection: a comparative overview, The Handbook of European IP Management, May 2012, co-authored with  Benjamin Bai and Paul B. Keller
  • Why France is a good forum for preliminary injunctions in patent matters, Global Business Magazine, April 2012
  • Supplementatry protection certificates: CJEU provides welcome clarifications, Who's Who Legal, Life Sciences, April 2012, co-authored with Olivia Klimis
  • Trade secrets protection, Commerce International, April 2012
  • L'arrêt DHL/Chronopost de la CJUE du 12 avril 2011 : une injonction communautaire peut être obtenue dans les limites de l'atteinte aux fonctions de la marque, Revue Lamy Droit de l'immatériel, August/September 2011, co-authored with Alexandra Abello
  • Competition, Public Health, Innovation and Drugs, LGDJ, 2010, under the supervision of Marie-Anne Frison-Roche
  • Generic drugs and IP law, Lamy Droit de la Santé, 2002, 2004 and 2008
  • Question 202 of the AIPPI French group on "The impact of public health issues on exclusive patents rights", September 2008
  • The DADVSI law regarding television: three steps backward for right owners?, Legipresse, May 2007, co-authored with Alexandre Rudoni
  • Rights owners and users fail to agree on reform, Managing Intellectual Property, June 2006, co-authored with Alexandre Rudoni
  • How to prepare the businessmen in the biotechnology sector for the cession of their firm, Bio Futur, October 2005, co-authored with Alexandre Rudoni